Thymoma is a chemotherapy-sensitive tumor with a 30-50% 5-year survival in previously untreated patients. Unfortunately, durable CRs with salvage chemotherapy are rarely observed. We initiated a phase II trial of high-dose carboplatin and etoposide in patients with relapsed thymoma or thymic carcinoma. All patients had progressive disease (PD) after initial or salvage chemotherapy, but were not cisplatin-refractory. PBSCs were mobilized using 10 g/kg/day G-CSF. Patients received carboplatin 700 mg/m 2 and etoposide 750 mg/m 2 i.v. on days −5, −4, −3. Five patients were enrolled and evaluated after tandem transplants 4 weeks apart. All patients had pleural-based and lung parenchymal metastasis, one or two prior surgeries and two or more courses of prior cisplatin-based chemotherapy regimens. Chemotherapy was well tolerated, although grade IV hematological toxicity occurred in all patients. Progression-free survival following HDC ranged from 3.5 to 16.5 months. One patient maintained a CR for 12.8 months, then died from an unrelated cause. With a minimum of 2 years follow-up for all patients, three of five patients remain alive at 26+, 36+, and 49+ months. High-dose carboplatin and etoposide in relapsed thymoma is feasible with acceptable toxicity; however, these limited data do not appear superior to standard-dose salvage therapy. Bone Marrow Transplantation (2001) 28, 435-438. Keywords: autologous stem cell transplantation; thymoma; relapsed disease Thymomas are infrequent tumors, but are the most common neoplasm of the anterior mediastinum.
Thymomas are infrequent tumors, but are the most common neoplasm of the anterior mediastinum. 1 They are chemosensitive with objective responses observed with single agent and combination chemotherapy. For patients with unresectable locally advanced disease, cisplatin, doxorubicin plus cyclophosphamide (PAC) produced an overall response rate of 70% prior to radiation therapy and 5-year overall survival of 52.5% in a small prospective intergroup trial. 2 However, durable CRs are rarely observed with standard salvage chemotherapy for relapsed disease.
Indiana University has experience with high-dose carboplatin and etoposide in the treatment of high risk and relapsed germ cell tumors. Patients with testicular cancer who are not cured with cisplatin-combination chemotherapy and aggressive surgical extirpation can achieve long-term remissions and cures with high-dose carboplatin and etoposide followed by peripheral blood stem cell (PBSC) transplantation. 3 Based on the germ cell model, we initiated this phase II study to investigate the efficacy of high-dose carboplatin and etoposide with PBSCT in patients with recurrent thymoma or thymic carcinoma. This approach was supported by a trial conducted by the EORTC which reported a 50% response rate in patients treated with conventional dosage cisplatin plus etoposide in advanced thymoma. 4 
Materials and methods
All eligible patients had histologic evidence of thymoma or thymic carcinoma and progressed after initial or salvage chemotherapy, but were not cisplatin-refractory (defined as recurring less than 2 months after cisplatin-based therapy). Patients must have had bidimensionally measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, creatinine clearance у60 cc/min, total bilirubin р2.0 mg/dl or SGOT/ SGPT р twice normal (unless due to hepatic metastases), a diffusion capacity у50% predicted, and a left ventricular ejection fraction of у50% to be eligible. In addition, patients may not have received more than three regimens of systemic chemotherapy prior to entry. All patients gave written informed consent.
Patients could have received standard doses of induction chemotherapy prior to transplant at the discretion of their physician. G-CSF was administered at 10 g/kg/day subcutaneously for at least 4 days prior to beginning stem cell collection and continued until the stem cell collection was complete. Stem cells were collected by apheresis until у10 × 10 8 nucleated cells/kg were reached. Patients received high-dose chemotherapy (HDC) with carboplatin and etoposide based on actual body weight unless this exceeded their ideal body weight by more than 20%. In these cases, chemotherapy was dosed on adjusted ideal body weight = ideal body weight + [0.5 (adjusted body weight − ideal body weight)]. Etoposide was administered at a dose of 750 mg/m 2 i.v. over 2 h on days −5, −4 and −3; carboplatin was administered at a dose of 700 mg/m 2 i.v. over 15-30 min on days −5, −4 and −3 following etoposide. Autologous PBSC were infused on day 0 (over 1-2 days at the discretion of the physician). A minimum of 5 × 10 8 nucleated PBSC per kg actual weight was required for each cycle. G-CSF was administered at 5 g/kg/day subcutaneously beginning on day 0 and continued until the absolute granulocyte count was Ͼ2000/mm 3 for 2 consecutive days or Ͼ10 000/mm 3 for 1 day. Patients were considered for a second course of HDC if they responded to the first course with a CR, PR or stable disease (SD), attained hematopoietic reconstitution, were free of active infections and had adequate renal and liver function.
All patients had a history taken and physical examination, noting ECOG PS, complete blood count (CBC) with platelets and differential, electrolytes, urinalysis, chest Xray (CXR) and/or CT scans as needed to document disease status. Bone marrow aspirates and biopsies were performed р1 month from the harvest date. All patients had pulmonary function testing with diffusing capacity, an electrocardiogram, evaluation of ejection fraction, and viral titers for CMV, herpes simplex and the HIV. Audiograms were optional.
A CR was defined as the absence of clinically detectable disease. A PR was defined as a у50% reduction in the sum of the perpendicular diameters of measurable lesions. For response evaluation after the final course of treatment, the above conditions had to be maintained for at least 1 month to be classified as a CR or PR. SD was defined as tumor regression not fulfilling the requirement for PR or tumor progression with Ͻ25% increase in the bidimensionally measurable tumor parameters. PD was defined as the appearance of new lesions and/or a у25% increase in measurable lesions. A CXR and other necessary imaging studies to evaluate measurable disease were performed every 2 months post transplant for the first year. CT scans of measurable disease were performed every 4 months during the first year post transplant, every 6 months during the second year, and annually for 3 additional years.
Statistical analysis
The primary objective of this phase II study was to evaluate the overall response rate to high-dose carboplatin and etoposide in patients with relapsed thymoma or thymic carcinoma. With 21 evaluable patients there would be a 91% power to detect an improvement from 5 to 25% in CR rate (one-sided alpha = 0.10). However, a two-stage design was used. 5 Initially, 11 patients were to be entered. If no CRs were observed, the trial would be terminated. If one or more CRs was observed, then 10 additional patients were to be entered. The 95% CI for the true response rate based on a two-stage design were calculated. 6 This trial, however, was closed early because of difficulties obtaining third party payment for treatment for this rare disease. Toxicities were reported in standard format.
Results
From April 1996 to October 1997, four patients with recurrent thymoma and one patient with recurrent thymic carcinoma were entered into the study. All patients were eligible and evaluable for response, survival and toxicity. Patient characteristics are listed in Table 1 . The minimum followup duration for all patients was 2 years with a maximum of 4+ years. Patient ages ranged from 32 to 53 years and all five patients had an ECOG PS of 0. Four patients were male. All patients had pleural-based and lung parenchymal metastasis, one or two prior surgeries and two or more courses of prior cisplatin-based chemotherapy regimens.
Transplant data is depicted in Table 2 . A median of 6.5 × 10 8 PBMC/kg were infused after each HDC. The mean number of days to granulocyte engraftment Ͼ500/mm 3 was 9.8 days (range 7-12) and the mean number of days to platelet engraftment Ͼ20 000/mm 3 was 17.4 days (10-38). Since no patients developed PD after the first course of HDC, all patients were eligible for and received their second course of HDC.
Toxicity
Chemotherapy was well tolerated but, as expected, grade IV hematological toxicity occurred in all patients as depicted in Table 3 . Grade 3 toxicities were (anemia, n = 4), nausea (n = 4), vomiting (n = 2), mucositis (n = 2), anorexia (n = 2), pericarditis (n = 1), hypomagnesemia (n = 1), liver (n = 1), and skin (n = 1). All patients required platelet transfusions during each tandem transplant. Four patients required blood transfusions during each tandem transplant. Three patients developed neutropenic fever with each tandem transplant, one patient with the second transplant only, and one patient who did not develop neutropenic fever with either transplant. There were no treatmentrelated fatalities.
Response and survival
Response to treatment and survival are depicted in Table  1 . Four of four patients responded to standard induction therapy immediately prior to treatment with HDC (three PR, one CR). One patient who achieved CR with induction therapy maintained this response with HDC for 12.8 months then died without documented progression from a motor vehicle accident. Three patients who achieved PR with induction chemotherapy maintained this response with HDC. No improvement in response was noted with the second course of HDC in any patient. One patient not treated with induction therapy attained a PR with the first course of HDC and maintained this response with the second course of HDC. Progression-free survival (PFS) following HDC ranged from 3.5 to 16.5 months. Three of five patients remain alive at 26+, 36+, and 49+ months from the first day of HDC.
Discussion
Thymomas are interesting tumors because of their variable clinical course, associated diseases and paraneoplastic syn- Histology: TC = thymic carcinoma; CT = cortical thymoma. Disease sites: l = lung; pl = pleura; pe = pericardium; m = mediastinum; ph = phrenic nerve; cw = chest wall; d = diaphragm. Rx: S = surgery; X = radiotherapy; C = cyclophosphamide; P = cisplatin; PAC = cyclophosphamide, doxorubicin, cisplatin; VeIP = vinblastine, ifosfamide, cisplatin; VIP = etoposide, ifosfamide, cisplatin; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; Oct = octreotide; pred = prednisone; dex = dexamethasone; Cap = capecitabine. Response (Resp): mPR = maintained PR; mCR = maintained CR. Table 3 Grade 3 and 4 Toxicities dromes. For patients with recurrent thymoma following surgery and/or radiation or for patients with metastatic disease, chemotherapy has shown some benefit. PAC yielded a 50% overall response rate in 30 patients, with a median duration of response of 11.8 months, a median survival of 37.7 months, and a 2-year survival of 64.5%. 7 Forniasiero and colleagues 8 have reported the results of adriamycin, cisplatin, cyclophosphamide and vincristine in 37 patients with stage III or IV disease showing a 91.8% response rate, including 16 CRs. The median duration of response and survival was 12 and 15 months, respectively. A small study of cisplatin and etoposide in patients with metastatic or recurrent disease resulted in a median survival of 4.3 years. 4 There remains no standard salvage regimen for relapsed thymomas, however. Salvage strategies have included cytokine therapy, where responses to IL-2 have been reported. 9 However, a larger study by Gordon and colleagues 10 failed to confirm activity with IL-2 in relapsed/refractory thymoma. Some patients with indolent disease may remain alive for up to 10 years with metastatic disease 11 and may benefit from surgical excision of recurrent disease. If surgery is not possible, radiotherapy has resulted in some long-term survivors. 12 Some patients who have responded to a conventional chemotherapy regimen, but relapse, may achieve another remission after retreatment with the same chemotherapy regimen. 13 In fact, patients may continue to respond to salvage chemotherapy, but unfortunately, there have been few durable complete remissions with this strategy. 14 Corticosteroids take advantage of the lymphocytic component of many thymomas and may benefit some patients. [15] [16] [17] Octreotide combined with prednisone has been shown capable of inducing CRs. 18, 19 A phase II study of two somatastatin analogs with prednisone resulted in two CRs, five PRs, and six SD in 13 evaluable patients in the salvage setting. 19 Other drugs with reported or observed activity in recurrent thymic malignancies include 5-fluorouracil, ifosfamide, gallium nitrate, and paclitaxel.
Three reports on the use of HDC in relapsed thymoma can be found in the literature. [20] [21] [22] Musi and colleagues 20 report a patient with resected stage III disease treated with adjuvant radiotherapy, who had a recurrence 7 years later. The patient demonstrated sensitive relapses to initial and salvage chemotherapy before receiving high-dose ifosfamide, carboplatin and etoposide and ABMT which resulted in a subtotal regression. Iwasaki and colleagues 21 published a report of a patient with an incomplete resection of a stage IVa thymoma who received two courses of postoperative cisplatin, doxorubicin, vincristine, and cyclophosphamide. PBSC collection utilizing moderate-dose etoposide and G-CSF followed by high-dose ifosfamide, carboplatin, etoposide and PBSCT was then administered. CR was confirmed by repeat thoracotomy. Gaspard and colleagues 22 reported on a series of 26 patients with poor-risk malignancies including two patients with relapsed thymoma who received high doses of BCNU, etoposide, Ara-C, and melphalan followed by ABMT. Both patients had previously been treated with radiotherapy and two or three prior chemotherapy regimens, but developed PD prior to ABMT. Both attained a CR with the HDC. One patient died 10 months later from relapsed thymoma, while the other remained alive and disease-free for 22+ months.
Our report of HDC in recurrent thymoma is the only other published series in the literature to our knowledge. We demonstrated that high-dose carboplatin and etoposide with PBSCT is feasible with acceptable toxicity; however, these limited data do not appear superior to standard-dose salvage therapy. The conclusions of this trial are limited because of the small number of patients treated. The treatment of recurrent thymoma in patients with minimal prior therapy requires further investigation, particularly because of the relatively high degree of, and diverse activity to chemotherapy. HDC remains a viable option for investigation and the optimal regimen is still undefined.
